When the COVID-19 pandemic struck more than a year ago, biopharmaceutical companies responded swiftly and worked tirelessly to develop COVID-19 vaccines, treatments and diagnostics. Since then, vaccine candidates have endured rigorous testing through multiple phases of clinical trials and regulatory review. As health authorities continue to monitor the safety and efficacy of these medicines and approve them for public use, it is important for people to know that manufacturers followed a rigorous testing process, including tens of thousands of people.
Scientists, health care professionals and government leaders across the Middle East and North Africa have collaborated this year to find innovative solutions to the ongoing COVID-19 pandemic. While it’s been an unprecedented year, it has also spurred immense biopharmaceutical research and development as industry innovators worked to leverage decades of research and scientific knowledge to develop new treatments and vaccines.
While the COVID-19 pandemic continues to have an unprecedented impact on the health of communities and global economies, government leaders at the G20 and World Health Assembly discussed various approaches to controlling the spread of COVID-19 through science-based solutions.
In a recent interview with Asharq Alawsat, Samir Khalil, Executive Director of the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa, discussed the ongoing need for strong intellectual property (IP) protections, increased investment in biopharmaceutical research and development and global collaboration to foster a robust innovation ecosystem in Saudi Arabia.